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Our newly generated murine tumor dendritic cell (MuTuDC) lines, generated from tumors
developing in transgenic mice expressing the simian virus 40 large T antigen (SV40LgT)
and GFP under the DC specific promoter CD11c, reproduce the phenotypic and functional
properties of splenic wild type CD8α+ conventional DCs. They have an immature pheno-
type with low co-stimulation molecule expression (CD40, CD70, CD80, and CD86) that is
upregulated after activation with toll-like receptor ligands. We observed that after transfer
into syngeneic C57BL/6 mice, MuTuDC lines were quickly rejected.Tumors grew efficiently
in large T transgene-tolerant mice. To investigate the immune response toward the large
T antigen that leads to rejection of the MuTuDC lines, they were genetically engineered
by lentiviral transduction to express luciferase and tested for the induction of DC tumors
after adoptive transfer in various gene deficient recipient mice. Here, we document that
the MuTuDC line was rejected in C57BL/6 mice by a CD4T cell help-independent, perforin-
mediated CD8 T cell response to the SV40LgT without pre-activation or co-injection of
adjuvants. Using depleting anti-CD8β antibodies, we were able to induce efficient tumor
growth in C57BL/6 mice.These results are important for researchers who want to use the
MuTuDC lines for in vivo studies.
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INTRODUCTION
The simian virus 40 large T antigen (SV40LgT) is a viral onco-
protein capable of transforming murine cells and recognized to
induce tumorigenesis by binding to and inhibiting specific cel-
lular tumor suppressor proteins such as p53 or retinoblastoma
protein (pRb). However, immunocompetent C57BL/6 mice are
protected against SV40LgT tumorogenesis after adoptive transfer.
Indeed C57BL/6 mice are able to mount a specific MHC-I cyto-
toxic response to the SV40LgT oncogene through the recognition
of four H-2b restricted cytotoxic epitopes inside the large T antigen
sequence (1, 2). Consequently, immunization of immunocom-
petent C56BL/6 mice with tumor cells expressing the SV40LgT
oncogene results in a strong cytotoxic T lymphocytes (CTL)
response leading to tumor rejection. Consequently, the CD8 T cell
response was required for the rejection of the SV40 Large T tumors.
This cytotoxic response can be mediated through various con-
tact dependent pathways in the immunological synapse including
Fas, tumor necrosis factor (TNF), TNF-related apoptosis-inducing
ligand (TRAIL), or granule exocytosis.
We show here that the transfer of newly developed murine
tumor dendritic cell (MuTuDC) lines derived from splenic
tumors of transgenic CD11c:SV40LgT mice (3, 4) into immuno-
deficient hosts (Rag2−/−) and transgene-tolerant mice (transgenic
CD11c:SV40LgT) resulted in the development of splenic and
hepatic DC tumors. In contrast, syngeneic immunocompetent
C57BL/6 mice were resistant to the development of the MuTuDC
tumor. Due to the lack of rejection in Rag2-deficient mice, we
postulated that DC lines are immunogenic and are rejected in WT
mice due to their ability to mount an immune response against
the antigens inherent to the transgene of the MuTuDC lines, i.e.,
the SV40LgT oncogene and/or GFP.
As these cell lines are more and more utilized by different groups
in research and it is often too cumbersome to breed all the recipient
KO and transgenic mice to Rag deficiency or transgene tolerance,
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we wanted to characterize the rejection mechanisms to allow adop-
tive transfer into immune-competent mice. In order to investigate
the mechanism of rejection of the MuTuDC lines, we lentivirally
transduced the MuTuDC lines with luciferase as a reporter to fol-
low tumor growth by non-invasive in vivo imaging. Using various
recipient mice and depleting antibodies, we observed a striking
tolerance to growth of MuTuDC lines in mice devoid of CD8+ T
cells or perforin and conclude that MuTuDC lines were rejected
from C57BL/6 mice via perforin-mediated lysis by CD8+ T cells.
We additionally show that the rejection is CD4 T cell indepen-
dent. The rejection was due to a fulminant immune CD8 T cell
response against the large T antigen. This finding allows efficient
transfer of MuTuDCs into immune-competent mice after CD8β
depletion using monoclonal antibodies. Interestingly, despite the
fact that immature DC usually induces tolerance, the cell line did
not require activation to induce protective tumor immunity.
MATERIALS AND METHODS
MOUSE STRAINS
C57BL/6 mice were purchased from Harlan laboratories. Rag2−/−,
Ubi-GFP, pfn-deficient, CD3- deficient, generalized lymphopro-
liferative disease (Gld), CD11c-eGFP-DTR, and CD11c:SV40LgT
mice were maintained under specific-pathogen free conditions
in our animal facility. In each experiment, at least three mice of
each strain were used and the animals were aged between 6 and
12 weeks. The experiments were performed in a conventional ani-
mal facility. The experiments were approved and controlled by the
Swiss cantonal and federal veterinary authorities as well as by the
local animal facility (Permission No. 2492).
MuTuDC LINES
MuTuDC lines, named for murine tumor, are derived from splenic
tumors in transgenic CD11c:SV40LgT C57BL/6 mice (3). The
derivation method is described in Ref. (4) and the MuTuDC
lines display the phenotypic and functional features of the nat-
ural splenic CD8α+ conventional DC. MuTuDC1940 line was
used for this study (4). MuTuDC lines were cultured in IMDM –
Glutamax (GIBCO) supplemented with 8% of heat-inactivated
fetal calf serum (FCS), 10 mM HEPES (GIBCO), 50µM β-
mercaptoethanol (GIBCO), 50 U/ml of penicillin, and 10µg/ml
streptomycin (GIBCO) at 37°C in 5% CO2 atmosphere. These
cells were harvested in a non-enzymatic cell dissociation buffer
(PBS 1×, 10 mM HEPES, and 5 mM EDTA). The number of cells
was determined by using the Casy® cell counter.
ANTIBODIES
Hybridoma cell line producing H35 was grown in IMDM cul-
ture medium supplemented with 2% of IgG-depleted FCS, 10 mM
HEPES, and 50µM β-mercaptoethanol at 37°C in 5% CO2 atmos-
phere. The anti-CD8β mAb was purified from cell culture super-
natant of the H35 hybridoma on Protein G sepharose column
(Amersham). Before immuno-staining, dead cells were excluded
with the fixable viability dye eFluor506 (eBioscience). All antibod-
ies used for flow cytometry experiments were diluted in an anti-
mouse Fc receptor mAb purified from the supernatant of culture
of the 2.4G2 hybridoma. Fluorochrome-conjugated monoclonal
antibodies for flow cytometry were purchased from eBioscience:
CD3-eFluor450 (eBio500A2), CD11c-PECy7 (N418), CD8α Per-
CpCy5.5 (53-6.7), CD62L Alexa Fluor700 (MEL-14), CD44 APC
(IM7), and IFNγ PECy7 (XMG1.2) or BioLegend: CD19 PE (6D5)
and CD4 APCCy7 (RM4-5). Analyses were performed with the
FACSLSRII or FACSCanto machines (Becton Dickinson) using the
FACSDiva software for the acquisition and the FlowJo software for
data analyses.
GENERATION OF Luc-DC
The amplification of the Photinus pyralis luciferase gene was per-
formed by PCR from the ISRE cis-reporter plasmid (Stratagene),
kindly provided by Professor Jürg Tschopp’s group. Oligonu-
cleotides used as PCR primers were synthesized according to the
NCBI sequences: forward primer: 5′-GATCGGATCCGCCACC
ATGGAAGACGCCAAAAACAT-3′ and reverse primer: 5′-GATC
GTCGACTCACAATTTGGACTTTCCGCCCT-3′. The amplifica-
tion was carried out with 0.2 mM dNTP (Roche), 1× expand high
fidelity buffer (Roche), 0.35 units expand high fidelity polymerase
(Roche), 4 mM MgCl2, 0.5 mM luciferase specific primers, and
0.1 ng ISRE cis-reporter plasmid. The first 10 cycles consist of 30 s
at 94°C, 30 s at 56°C, and 70 s at 72°C with a loss of 1°C for the
annealing step at each cycle, followed by 20 cycles of 30 s at 94°C,
30 s at 46°C, and 70 s at 72°C, followed by a final extension at 72°C
for 10 min.
The luciferase PCR product and the (pWP-SIN-cPPT-WPRE)-
CMV-IRES-GFP lentivirus vector were digested by BamHI
and SalI (New England Biolabs). The purified insert was lig-
ated into the prepared (pWP-SIN-cPPT-WPRE)-CMV-IRES-GFP
lentivirus vector with 20 units of T4 DNA ligase (Rapid ligation
kit, Promega). The transduction was done into the MuTuDC1940
line as previously described (4, 5).
DETECTION OF LUCIFERASE EXPRESSION
The luciferase expression was checked by measuring the luciferase
activity in Luc-DC by using the luciferase assay system kit
(Promega) and the TD-20/20 Luminometer (Promega). The
2× 106 Luc-DC or parental MuTuDC lines were used for the
experiment. The light emission was measured as relative light units
(RLU). The luciferase activity in Luc-DC was also measured by
using the Xenogen imaging system (Xenogen/Caliper life science,
Platform of the Cellular Imaging Facility (CIF), University of Lau-
sanne). From 1575 to 100,000 Luc-DC or parental MuTuDC lines
were plated into a 96-well plate and the bioluminescence was mon-
itored after addition of 0.15 mg/ml of d-luciferin and quantified
as photons/s/cm2/sr.
ADOPTIVE TRANSFER OF THE MuTuDC LINES AND BIOLUMINESCENCE
IMAGING OF THE DC TUMOR DEVELOPMENT
The 5× 106 MuTuDC lines were injected by the intravenous (iv)
route into the tail vein of mice. Clinical signs of tumor devel-
opment were followed daily and mice were sacrificed when they
showed reduced hematocrits. Upon transfer of 5× 106 Luc-DC
cells, the DC tumor development was monitored after intraperi-
toneal (ip) injection of 1.5 mg/100µl of d-luciferin (Promega,
VivoGlo™ Luciferin) using the Xenogen imaging system. The
images were analyzed using the LivingImage3.2 software and the
luminescence was quantified as photons/s/cm2/sr.
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IN VIVO DEPLETION OF CD4+, CD8β+, AND CD11C+ CELLS USING MAB
OR DT TREATMENT
Two days before and 3 days after Luc-DC injection, C57BL/6 mice
were injected ip with 100µg of anti-CD8β clone H35 mAb or
750µg GK1.5 ascites fluid. The in vivo depletion of lymphocyte
population was confirmed by flow cytometry by examining blood
cell population and was above 97%. CD11c-eGFP-DTR mice and
littermates were treated by ip injection with 4 ng of DT per gram of
weight 1 day before the iv injection of Luc-DC. The in vivo deple-
tion of CD11c+ cells was analyzed by flow cytometry in the spleen
1 day after the DT injection.
EX VIVO RESTIMULATION OF SPLENOCYTES
When tumor-bearing mice displayed clinical symptoms, all Luc-
DC injected mice were sacrificed (about 15–20 days following
Luc-DC transfer according to the experiment) and spleens were
digested by incubating organs for 20 min at 25°C in 1 mg/ml
collagenase D (Roche), 40µg/ml DNAse I (Roche) in RPMI
1640 (GIBCO) supplemented with 50µg/ml gentamycin, 5%
FCS, and 1 mM HEPES. Cells were washed with complemented
RPMI medium and 5µg/ml DNAse I and mechanically dis-
rupted on a 40-µm nylon cell strainer. Erythrocytes were lysed
with the red blood cell lysis buffer (0.01 M KHCO3+ 0.155 M
NH4Cl+ 0.1 mM EDTA, pH 7.5) and cells were counted using
the Casy® cell counter. The 0.3× 106 splenocytes were restim-
ulated or not with 1× 104 parental MuTuDC line previously
seeded. In other experiments, splenocytes were restimulated or
not with 0.3× 106 C57BL/6 splenocytes and 8.1µg of recom-
binant SV40LgT protein (ChimerX). After 4 days, T cells were
restimulated with 10 ng/ml of PMA (Sigma), 500 ng/ml of ion-
omycin (Calbiochem), and 10µg/ml of brefeldin A (Sigma) for
4 h at 37°C and the activation and differentiation state of T cells
were assessed by flow cytometry. Supernatants were assessed for
IFNγ secretion by ELISA by using kits from eBioscience according
to the provider’s instructions.
STATISTICAL ANALYSES
When indicated, statistical analyses were performed with Prism
software. Differences between two groups were assessed by a two-
ways ANOVA test followed by Bonferroni post hoc test (*p< 0.05;
**p< 0.005; ***p< 0.001).
RESULTS
C57BL/6 MICE ARE RESISTANT TO SYNGENEIC MuTuDC TUMOR
DEVELOPMENT BY AN ADAPTIVE RESPONSE
Upon adoptive transfer of the MuTuDC lines, C57BL/6 mice
did not develop DC tumors (Figure 1). The mice were sacri-
ficed 200 days post-injection and no signs of splenomegaly or
hepatosplenomegaly were observed. Conversely, upon transfer of
the MuTuDC lines into immunocompetent transgene-tolerant
CD11c:SV40LgT mice, hepatic and splenic tumors developed
readily (Figure 1). Two CD11c:SV40LgT mouse lines exist, one
with fast-developing tumors (line 13, tumors at 3.5 months,
from which most MuTuDC lines were originally derived), and
the second one with slow-developing tumors (line 2, tumors at
12 months) (3). Line 2 mice were used in the transfer exper-
iment to avoid growth of endogenous tumors and the ability
FIGURE 1 | MuTu tumors developed in tolerant CD11c:SV40LgT and
Rag-deficient mice but not in immunocompetent C57BL/6 mice.
Five×106 MuTuDC lines were transferred by iv route into C57BL/6 (n=19),
CD11c:SV40LgT (n=19), or Rag2−/− mice (n=9). The percent of survival
was displayed according to the day post-injection.
to distinguish endogenous from transferred tumors due to dif-
ferent eGFP expression levels distinguishable by flow cytome-
try. CD11c:SV40LgT line 2 mice developed splenomegaly and
hepatomegaly in average 1 month after the MuTuDC line trans-
fer, instead of after 12 months without transfer. Furthermore,
after transfer of the MuTuDC lines into Rag2−/− mice, lack-
ing T and B cells due to the absence of the recombina-
tion activating gene, the mice developed tumors in the liver
and the spleen in about 1 month (Figure 1). These Results
indicated that the induction of an anti-tumor immunity in
C57BL/6 mice is inherent to tumor antigens expressed by the
MuTuDC lines and that the tumor protection is mediated by
a T and/or B cell response eliminating the DC tumors in
C57BL/6 mice.
GENERATION OF LUCIFERASE-EXPRESSING MuTuDC LINE
To investigate the MuTuDC line clearance mechanism in C57BL/6
mice, we generated a luciferase-expressing MuTuDC line by
lentiviral transduction (named Luc-DC hereafter). The efficacy
of the lentiviral transduction was determined by the measure of
the bioluminescence activity of Luc-DC after 1 week (Figure 2A)
and was stable for up to 10 passages in culture (data not shown).
The emission of bioluminescence was cell-number dependent
(Figure 2B). Consequently, Luc-DC efficiently expressed the
luciferase and were used to follow tumor development by in vivo
imaging in living animals.
DC TUMOR REJECTION IN SYNGENEIC MICE IS NOT COMPROMISED BY
LUCIFERASE EXPRESSION
In order to determine whether the luciferase expression did not
change the behavior of the MuTuDC lines in vivo, Luc-DC were
transferred into syngeneic C57BL/6, CD11c:SV40LgT, and Rag2-/-
mice and the Luc-DC expansion was followed by measuring the
bioluminescence signal. After iv injection, cells circulated and
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FIGURE 2 | Luc-DC efficiently expressed the luciferase. MuTuDC lines
were transduced with the lentivirus vector containing the gene encoding
the Photinus pyralis luciferase and the luciferase activity was controlled
in vitro. (A) The 2×106 cells were lysed and the bioluminescence was
quantified by using a luminometer after adding of the d-luciferin. The light
emission was measured as relative light units (RLU). (B) Different
numbers of cells were plated in triplicate in a 96-well plate and the
bioluminescence was monitored and quantified as photons/s/cm2/sr after
adding 0.15 mg/ml of d-luciferin by using the Xenogen imaging system.
Data are presented as mean±SD.
primarily localized to the lung, spleen, and liver. The biolumines-
cence signal decreased after 1 day and thereafter surviving Luc-DC
started to expand mainly in the liver and the spleen. Tumors com-
parably grew in CD11c:SV40LgT and Rag2-/- recipients. In vivo
imaging showed the implantation of the DC tumors in the spleen
and the liver 8 days after Luc-DC transfer (Figure 3A). Conversely,
after 8 days, no more luciferase activity was detected in C57BL/6
mice due to elimination of Luc-DC (Figure 3A). Consequently,
Luc-DC, similar to the parental MuTuDC lines, failed to expand
and develop tumors in C57BL/6 mice but induced tumors in
immuno-deficient and transgene-tolerant mice. Consequently, the
luciferase expression did not alter the MuTuDC lines and there-
fore Luc-DC nicely recapitulate the observations using the WT
MuTuDC lines, providing an imaging method to follow tumor
progression in vivo.
THE INITIAL LOSS OF MuTuDC LINES AT DAY 1 WAS NOT ALTERED BY
ENDOGENOUS DC DEPLETION
As observed in Figure 3A, the in vivo Luc-DC number declined
1 day following transfer into WT, Rag-deficient, and transgene-
tolerant mice. To investigate whether this reduced signal was due
to the absence of an available niche for the initial proliferation of
transferred cells, we used CD11c-eGFP-DTR recipient mice that
express the diphtheria toxin receptor (DTR) under the CD11c
promoter (6). CD11c+ cells were efficiently depleted in diph-
theria toxin (DT)-treated CD11c-eGFP-DTR mice (Figure 3B)
and this depletion could provide the space and resources required
for the expansion of the transferred DC lines. One day follow-
ing Luc-DC injection, the bioluminescence signal was equivalent
in DT-treated CD11c-eGFP-DTR, DT-treated CD11c-eGFP-DTR
littermates, and C57BL/6 mice (Figure 3C), therefore the depletion
of CD11c+ cells did not prevent the decrease in the biolumines-
cence signal observed at day 1 following Luc-DC transfer. Conse-
quently, the decline of Luc-DC numbers could not be explained
by the lack of a niche required for the initial expansion.
MuTuDC LINES WERE CLEARED IN C57BL/6 MICE BY
PERFORIN-PRODUCING CTL INDEPENDENT ON CD4 T CELL HELP
In order to investigate the mechanism by which MuTuDC lines are
cleared from C57BL/6 mice, Luc-DC were injected into CD3-KO
mice. As observed in Figure 4A,C, Luc-DC formed tumors in CD3-
deficient mice. To further explore the T cell-mediated rejection,
tumor development was assessed in CD8β- and CD4-depleted
C57BL/6 mice after Luc-DC challenge. The effective depletion was
of 97% for CD8+ T cells and superior to 98% for CD4+ T cells
(Figure 4B). Eight days after challenge, Luc-DC were cleared from
WT and CD4-depleted C57BL/6 mice, whereas CD8β-depleted
mice failed to eliminate the MuTuDC lines leading to tumor out-
growth (Figure 4A,C). Therefore, the elimination of Luc-DC in
C57BL/6 mice is dependent on CD8+ T cell-dependent killing and
does not require CD4 T cell help. Furthermore, Luc-DC tumors
grew progressively in perforin (Pfn)-deficient mice but not in
FasL-deficient mice (Gld) upon transfer (Figure 4A,D). Conse-
quently, the loss of perforin-dependent cytolytic function breaks
the immune resistance and allows tumor outgrowth.
ONLY CD8+ T CELLS FROM TUMOR-REJECTING MICE RESPONDED
STRONGLY AFTER IN VITRO RESTIMULATION
To further analyze the CTL response, splenocytes from Luc-
DC-injected mice were ex vivo restimulated with the parental
MuTuDC lines (not expressing Luciferase). After 4 days of co-
culture of splenocytes with DC lines, we observed a CD8+
T cell response that was markedly higher in splenocytes from
the C57BL/6, CD4-depleted, and FasL-deficient mice than
in splenocytes from the tumor-bearing CD8β-depleted, Pfn-
deficient, and CD11c:SV40LgT hosts (Figure 5A,B). These CD8+
T cells expressed the activation marker CD44 and produced
IFNγ (Figure 5C–E). Conversely, very small numbers of CD4+
were detected and only weakly upregulated CD44 and IFNγ
(Figure 5C), confirming the CTL-mediated response to the
MuTuDC lines.
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FIGURE 3 | C57BL/6 mice are resistant to Luc-DC line tumor and the
depletion of endogenous CD11c+ cells did not provide a niche for the
initial expansion of MuTuDC line. Five×106 Luc-DC were transferred by iv
route and the DC tumor growth was followed over time by bioluminescence
measurement using the Xenogen imaging system after ip injection of 1.5 mg
of d-luciferin. The bioluminescence was quantified as photons/s/cm2/sr.
(A) The tumor development was followed in C57BL/6 (n=9), CD11c:SV40LgT
(n=6), and Rag2-/- (n=6) mice at days 0, 1, 4, 8, and 13 following the transfer
of Luc-DC. One representative mouse is shown. (B) CD11c-eGFP-DTR
littermates (upper panel) and CD11c-eGFP-DTR mice (bottom panel) were
injected with DT and the efficiency of the depletion of CD11c+ cells was
checked in the spleen 24 h later by flow cytometry (gated on single CD3-
CD19- cells). (C) Luc-DC were transferred into C57BL/6 (n=7), DT-treated
CD11c-eGFP-DTR (n=8), and DT-treated CD11c-eGFP-DTR littermates (n=7)
mice. CD11c-eGFP-DTR mice were treated with the DT, 1 day prior the
transfer of the Luc-DC. The tumor growth was assessed just after the transfer
and at day 1. Data are presented as mean±SD. The p values were
determined by a two-way ANOVA with Bonferroni post-test.
DISCUSSION
MuTuDC lines are immunogenic and are quickly rejected upon
transfer into H-2b C57BL/6 mice by a perforin-mediated CD4
T cell independent of CD8+ T cell response. DC tumor devel-
opment in Rag-deficient mice suggests that NK cells were not
sufficient to induce MuTuDC line rejection and the presence of
tumor development in perforin-deficient mice demonstrated that
other known mechanisms of cytotoxicity (7) are not important
for tumor clearance and of minor importance.
We assume here that this CD8 T cell response is mediated
against the transgenic SV40LgT and not the GFP endogenous to
the MuTuDC lines. Indeed Ubi-GFP mice were able to eliminate
the MuTuDC lines. The transfer of the MuTuDC lines into GFP-
expressing mice did not induce DC tumor outgrowth meaning
that SV40LgT antigen alone was sufficient to induce the protec-
tive anti-tumor immunity. In addition, using recombinant large T
protein, we were able to show reactivity of splenocytes of MuTuDC
immunized mice to this antigen in vitro (Figure S1 in Supplemen-
tary Material). The anti-tumor response could not be attributed
to the luciferase expressed by the injected Luc-DC since first,
luciferase has been shown to be poorly immunogenic (8, 9); sec-
ond, Luc-DC induce tumors in large T and GFP-tolerant mice;
and third, because CD8+ T cells isolated from tumor-free Luc-
DC-injected C57BL/6 mice highly proliferated in vitro in response
to the parental MuTuDC lines devoid of luciferase expression.
We also can exclude that the MuTuDC lines reveal new antigens
in C57BL/6 recipients due to modifications acquired during the
in vitro immortalization since tumors easily grew in mice tolerant
to CD11c:SV40LgT.
The decline of Luc-DC numbers during the first day after trans-
fer could be attributed to the death of injected cells as it was not
reverted by providing niche spaces. Indeed several studies showed
that radioactive-labeled tumor cells died by apoptosis in the lung
during the 24 h following the administration into the blood cir-
culation (10, 11). It is coherent with the localization of Luc-DC in
the lung in the hours following the injection.
It is intriguing that the transfer of the MuTuDC lines into
C57BL/6 mice elicited an unhelped strong anti-tumor CD8 T cell
response. DC that were not pre-activated by TLR ligands and dis-
play the same or lower level of activation markers (co-stimulation
molecules and MHC-II) as freshly isolated splenic DC (3, 4) did
not induce tolerance but rather immunity. Furthermore, no“spon-
taneous” activation of MuTuDC lines was observed during the
culture and preparation of the cells as already observed for ex vivo
isolated DC (12). Consequently, it is contrary to the concept in
which DC have to be previously treated with maturation stim-
uli to induce an efficient T cell response (13–15). Thereby, a high
immunogenicity or a transfer of a high number of MuTuDC lines
allows counteracting the requirement of a previous maturation
to induce immunity. Moreover, we demonstrated that the rejec-
tion of MuTuDC lines was mediated by an unhelped CD8 T cell
response. However, in the literature, a protective anti-tumor CD8
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FIGURE 4 | Perforin-producing CD8+ T cells protect C57BL/6 mice from
DC tumor development. (A) The tumor growth was detected by monitoring
the bioluminescence after iv injection of 5×106 Luc-DC into C57BL/6 (n=12),
CD3-KO (n=3), CD8β-depleted C57BL/6 (n=9), CD4-depleted C57BL/6
(n=6), Pfn−/− (n=6), and Gld (n=6) recipient mice at different time points.
The bioluminescence was assessed by using the Xenogen imaging system
after ip injection of 1.5 mg of d-luciferin at days 0, 1, 4, 8, and 13 after Luc-DC
injection. (B) Two days before and 3 days after Luc-DC injection, 100µg of
CD8β- or CD4-depleting antibody were administrated into C57BL/6 mice by ip
injections. The effective depletion of CD8+ and CD4+ cells was checked by
flow cytometry in the blood 1 day after the last injection (gated on single live
cells). (C,D) The bioluminescence measured in the various mouse strains was
quantified as photons/s/cm2/sr. Data are presented as mean±SD. The p
values were determined by a two-way ANOVA with Bonferroni post-test.
immunity is associated with the CD4 T cell help (16) and thus the
requirement of CD4 T cell helps to induce the CD8 T cell response
to tumors that could be substituted by the high immunogenicity
and frequency of MuTuDC lines.
After ex vivo restimulation, we observed a strong CD8 T cell
response in tumor-free mice whereas the CD4 T cell response was
low. In tumor-bearing mice, an anti-tumor CD8 T cell response
was observed ex vivo but lower than the one observed in tumor-free
hosts. We observed the following hierarchy in immune response
in tumor-bearing mice: the CD8 T cell response was superior in
CD8β-depleted mice and equivalent in pfn-deficient and SV40LgT
and GFP-tolerant mice. In CD8β-depleted mice, we speculate that
newly developed CTL were rendered tolerant in vivo and therefore
were unable to control tumor growth as already described in a spo-
radic tumor model. Tumor cells were immunogenic and induced
tolerance to a cellular anti-tumor immunity, not able to protect
mice from tumor development (17). The lower tumor-specific
proliferative response of pfn-deficient CTL was surprising as
several studies showed that perforin-deficient mice exhibited an
exaggerated CTL immune response upon infections (18–20). The
mechanisms of partial tolerance induction have to be investigated
but we speculate that in tumor-bearing mice, perforin-deficient
CD8+ T cells were exhausted due to tumor environment. How-
ever, we could not exclude that CD8+ T cells in perforin-deficient
mice were not primed after MuTuDC line injection. Indeed sev-
eral studies showed that the priming of T cells in DC vaccination
relied on the transfer of antigens to endogenous DC that capture
and present antigens from injected/killed DC to CD8+ T cells
(21, 22). The deficiency in perforin could avoid the killing of
injected cells and therefore render unable the capture of antigens
by endogenous APC. This hypothesis is supported by the absence
of proliferation of ova-specific CD8+ T cells observed after injec-
tion of ova-loaded MuTuDC lines in Kb−/−, β2m−/−, Batf3−/−,
and CD11c-depleted mice whereas OT-I T cells nicely proliferated
in C57BL/6 mice (data not shown). Surprisingly, CD8+ T cells
from transgene-tolerant mice also responded to MuTu DC lines
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FIGURE 5 | CD8+ T cells from tumor-free mice highly proliferated after
ex vivo restimulation with the parental MuTuDC lines. (A,B) Mice
were sacrificed 14 days after Luc-DC transfer and 3×105 splenocytes
were ex vivo restimulated with 1×104 MuTuDC lines (upper panel) or left
untreated in 96-well plate (lower panel). After 4 days, the CD8 and CD4 T
cell response was analyzed by flow cytometry (A) and the numbers of
CD4+ and CD8+ T cells after restimulation with MuTuDC lines were
quantified after gating on single CD3+ live cells (B). (C,D) The expression
of the activation marker CD44 and the production of IFNγ were analyzed,
after restimulation with the MuTuDC lines for 4 days, among CD8+ CD4−
cells (upper panel) and CD4+ CD8− cells (lower panel) after gating on
single CD3+ live cells (C) and the number of CD3+ CD8+ CD4− CD44+
IFNγ+ cells was quantified (D). (E) The secretion of IFNγ was assessed by
ELISA in the supernatant of culture after restimulation with the MuTuDC
lines for 4 days. Mean±SD is shown. Results are representative of two
independent experiments.
upon rechallenge whereas tolerance should be complete due to
antigen expression by all thymic DC. However, it could argue for
the presence of an antigen acquired by the MuTuDC lines during
the in vitro immortalization process and which elicits the CD8
T cell response. This argument is counteracted by the restimula-
tion of the CD8 T cell response with recombinant large T antigen.
These findings demonstrate that SV40-transformed non-activated
MuTuDC lines are immunogenic and thereby elicit a strong CD8
T cell response in syngeneic mice. As these DC lines are now
distributed worldwide, we wanted to investigate the behavior of
these cells in their syngeneic mouse strain because these DC lines
are expected to serve as a tool to help design of new strategies
for immunotherapies for the treatment of cancer and autoim-
mune disorders that then can be confirmed using classical DC
vaccination.
ACKNOWLEDGMENTS
We thank Muriel Rosa for the production and the purifica-
tion of anti-CD8β-depleting antibody; Nadia Corrazza from the
University of Bern for providing the Gld mice; Prof. S. Luther from
the University of Lausanne for providing CD11c-eGFP-DTR and
Ubi-GFP mice; Prof. J. Tschopp from the University of Lausanne
for giving the ISRE cis-reporter plasmid; Isabelle Dunand from
the CMU of Geneva for providing the lentivirus transduction sys-
tem; Florence Morgenthaler of the cellular imaging facility of the
University of Lausanne; and Danny Labes and Anne Wilson of the
flow cytometry facility of the Ludwig institute for cancer research,
Lausanne. The project was supported by a Swiss National Science
Foundation Grant to Hans Acha-Orbea.
SUPPLEMENTARY MATERIAL
The Supplementary Material for this article can be found online at
http://www.frontiersin.org/Journal/10.3389/fimmu.2014.00338/
abstract
REFERENCES
1. Tevethia SS. Recognition of Simian Virus-40 T-antigen by cytotoxic
lymphocytes-T. Mol Biol Med (1990) 7:83–96.
2. Mylin LM, Schell TD, Roberts D, Epler M, Boesteanu A, Collins EJ, et al. Quanti-
tation of CD8(+) T-lymphocyte responses to multiple epitopes from simian
virus 40 (SV40) large T antigen in C57BL/6 mice immunized with SV40,
www.frontiersin.org July 2014 | Volume 5 | Article 338 | 7
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Duval et al. CTL-dependent MuTuDC tumor rejection
SV40 T-antigen-transformed cells, or vaccinia virus recombinants express-
ing full-length T antigen or epitope minigenes. J Virol (2000) 74:6922–34.
doi:10.1128/JVI.74.15.6922-6934.2000
3. Steiner Q-G, Otten LA, Hicks MJ, Kaya G, Grosjean F, Saeuberli E, et al. In vivo
transformation of mouse conventional CD8α+ dendritic cells leads to progres-
sive multisystem histiocytosis. Blood (2008) 111:2073–82. doi:10.1182/blood-
2007-06-097576
4. Fuertes Marraco SA, Grosjean F, Duval A, Rosa M, Lavanchy C, Ashok D, et al.
Novel murine dendritic cell lines: a powerful auxiliary tool for dendritic cell
research. Front Immunol (2012) 3:331. doi:10.3389/fimmu.2012.00331
5. Salmon P, Trono D. Production and titration of lentiviral vectors. Curr Prot Hum
Genet (2007) 54:12.10.1–24. doi:10.1002/0471142905.hg1210s54
6. Jung S, Unutmaz D, Wong P, Sano G-I, De Los Santos K, Sparwasser T,
et al. In vivo depletion of CD11c+ dendritic cells abrogates priming of CD8+
T cells by exogenous cell-associated antigens. Immunity (2002) 17:211–20.
doi:10.1016/S1074-7613(02)00365-5
7. Russell JH, Ley TJ. Lymphocyte-mediated cytotoxicity. Annu Rev Immunol
(2002) 20:323–70. doi:10.1146/annurev.immunol.20.100201.131730
8. Skelton D, Satake N, Kohn DB. The enhanced green fluorescent protein (eGFP)
is minimally immunogenic in C57BL/6 mice. Gene Ther (2001) 8:1813–4.
doi:10.1038/sj.gt.3301586
9. Tiffen J, Bailey C, Ng C, Rasko J, Holst J. Luciferase expression and biolumines-
cence does not affect tumor cell growth in vitro or in vivo. Mol Cancer (2010)
9:299. doi:10.1186/1476-4598-9-299
10. Reid GH, Gibbins JR. Fate of cultured cells after injection into the circulation of
syngeneic animals. Cancer Res (1979) 39:4724–31.
11. Wong CW, Lee A, Shientag L, Yu J, Dong Y, Kao G, et al. Apoptosis: an early event
in metastatic inefficiency. Cancer Res (2001) 61:333–8.
12. Vremec D, O’keeffe M, Wilson A, Ferrero I, Koch U, Radtke F, et al. Factors deter-
mining the spontaneous activation of splenic dendritic cells in culture. Innate
Immun (2011) 17:338–52. doi:10.1177/1753425910371396
13. Bonifaz L, Bonnyay D, Mahnke K, Rivera M, Nussenzweig MC, Steinman RM.
Efficient targeting of protein antigen to the dendritic cell receptor DEC-205 in
the steady state leads to antigen presentation on major histocompatibility com-
plex class I products and peripheral CD8+ T cell tolerance. J Exp Med (2002)
196:1627–38. doi:10.1084/jem.20021598
14. Steinman RM, Nussenzweig MC. Avoiding horror autotoxicus: the importance
of dendritic cells in peripheral T cell tolerance. Proc Natl Acad Sci U S A (2002)
99:351–8. doi:10.1073/pnas.231606698
15. Probst HC, Mccoy K, Okazaki T, Honjo T, Van Den Broek M. Resting dendritic
cells induce peripheral CD8+ T cell tolerance through PD-1 and CTLA-4. Nat
Immunol (2005) 6:280–6. doi:10.1038/ni1165
16. Marzo AL, Kinnear BF, Lake RA, Frelinger JJ, Collins EJ, Robinson BW, et al.
Tumor-specific CD4+ T cells have a major“post-licensing”role in CTL mediated
anti-tumor immunity. J Immunol (2000) 165:6047–55. doi:10.4049/jimmunol.
165.11.6047
17. Willimsky G, Blankenstein T. Sporadic immunogenic tumours avoid destruc-
tion by inducing T-cell tolerance. Nature (2005) 437:141–6. doi:10.1038/
nature03954
18. Sad S, Kagi D, Mosmann TR. Perforin and Fas killing by CD8+ T cells lim-
its their cytokine synthesis and proliferation. J Exp Med (1996) 184:1543–7.
doi:10.1084/jem.184.4.1543
19. Matloubian M, Suresh M, Glass A, Galvan M, Chow K, Whitmire JK, et al. A role
for perforin in downregulating T-cell responses during chronic viral infection.
J Virol (1999) 73:2527–36.
20. Badovinac VP, Tvinnereim AR, Harty JT. Regulation of antigen-specific CD8+ T
cell homeostasis by perforin and interferon-gamma. Science (2000) 290:1354–8.
doi:10.1126/science.290.5495.1354
21. Yewdall AW, Drutman SB, Jinwala F, Bahjat KS, Bhardwaj N. CD8+T cell prim-
ing by dendritic cell vaccines requires antigen transfer to endogenous antigen
presenting cells. PLoS One (2010) 5:e11144. doi:10.1371/journal.pone.0011144
22. Petersen TR, Sika-Paotonu D, Knight DA, Simkins HM, Hermans IF. Exploit-
ing the role of endogenous lymphoid-resident dendritic cells in the priming of
NKT cells and CD8+ T cells to dendritic cell-based vaccines. PLoS One (2011)
6:e17657. doi:10.1371/journal.pone.0017657
Conflict of Interest Statement: The authors declare that the research was conducted
in the absence of any commercial or financial relationships that could be construed
as a potential conflict of interest.
Received: 08 May 2014; accepted: 03 July 2014; published online: 17 July 2014.
Citation: Duval A, Fuertes Marraco SA, Schwitter D, Leuenberger L and Acha-
Orbea H (2014) Large T antigen-specific cytotoxic T cells protect against dendritic
cell tumors through perforin-mediated mechanisms independent of CD4 T cell help.
Front. Immunol. 5:338. doi: 10.3389/fimmu.2014.00338
This article was submitted to Antigen Presenting Cell Biology, a section of the journal
Frontiers in Immunology.
Copyright © 2014 Duval, Fuertes Marraco, Schwitter , Leuenberger and Acha-Orbea.
This is an open-access article distributed under the terms of the Creative Commons
Attribution License (CC BY). The use, distribution or reproduction in other forums is
permitted, provided the original author(s) or licensor are credited and that the original
publication in this journal is cited, in accordance with accepted academic practice. No
use, distribution or reproduction is permitted which does not comply with these terms.
Frontiers in Immunology | Antigen Presenting Cell Biology July 2014 | Volume 5 | Article 338 | 8
